Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 5/20 | 0.55 |
| ▸ | CCNK | O75909 | 5/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.55 |
| ▸ | CDK2 | P24941 | 5/20 | 0.55 |
| ▸ | CDK9 | P50750 | 5/20 | 0.55 |
| ▸ | CDK12 | Q9NYV4 | 5/20 | 0.55 |
| ▸ | CDK7 | P50613 | 3/20 | 0.55 |
| ▸ | CCNH | P51946 | 3/20 | 0.55 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.55 |
| ▸ | AR | P10275 | 9/20 | 0.52 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.45 |
| ▸ | ATP4A | P20648 | 1/20 | 0.39 |
| ▸ | ATP4B | P51164 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957639 | 1.00 | CCNT1 (0.55) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL24900631 | 0.88 | RPS6KA5 (0.48) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL30957452 | 0.88 | RPS6KA5 (0.48) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL24900582 | 0.87 | RPS6KA5 (0.60) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL24588145 | 0.85 | CLK1 (0.53) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL22580149 | 0.85 | CLK1 (0.55) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL29699138 | 0.85 | CLK1 (0.53) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL17696390 | 0.84 | CCNT1 (0.57) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL30221492 | 0.84 | CCNT1 (0.57) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL24900752 | 0.84 | DYRK1A (0.50) | CCNT1CCNKCCNE1CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | ACEA Therapeutics, Inc. (US) | 2025-05-01 | — | — | US | disclosed |
| CN-118159533-A | Heterocyclic compounds and their use | 艾森医药有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4370212-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023287783-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287783-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | CHEK2, CDK2, CDK1 | CCNT1 590/4885CCNK 95/4885CCNE1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.